H.I.G. Capital, a prominent global alternative investment firm, continues to strengthen its foothold in the healthcare industry. With $65 billion in assets under management, the Miami-based firm has been active in acquiring companies that align with its growth strategy.
Recent strategic moves include the acquisition of SkinCure Oncology, a leader in image-guided superficial radiation therapy for nonmelanoma skin cancer. This acquisition places H.I.G. Capital in the thriving field of non-invasive cancer treatments, allowing it to tap into a market with increasing demand for innovative healthcare solutions. SkinCure Oncology has already partnered with over 500 physicians and treated more than 100,000 patients, highlighting its impact in the sector.
H.I.G. Capital also made headlines with the sale of BIOVECTRA, a contract development and manufacturing organization, to Agilent Technologies for $925 million. Under H.I.G.’s ownership, BIOVECTRA expanded its capabilities and focus, marking a period of significant growth. This sale underscores H.I.G. Capital’s ability to nurture and develop businesses into attractive assets for potential buyers.
Additionally, H.I.G. Capital ventured into the organic beauty market by acquiring a majority stake in Naturalia Tantum S.p.A., an Italian company known for its natural beauty and personal care products. This move signals H.I.G.’s interest in the booming natural products industry, which is experiencing a surge in consumer demand.
The firm has also broadened its scope with acquisitions in adjacent sectors, such as Action Elevator. While this may not seem directly related to healthcare, it supports essential infrastructure services that are crucial for healthcare facilities.
H.I.G. Capital’s recent activities highlight its strategic approach to diversifying investments and capitalizing on growth opportunities across various sectors. As the firm continues to expand its portfolio, its influence in the healthcare industry—and beyond—remains a critical focus.